Published in Mol Cancer Ther on July 01, 2007
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst (2013) 2.28
CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A (2011) 1.91
Resistance to Trastuzumab in Breast Cancer. Clin Cancer Res (2009) 1.86
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res (2011) 1.39
A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Res Treat (2008) 1.21
Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res (2014) 1.21
The anti-malarial chloroquine overcomes primary resistance and restores sensitivity to trastuzumab in HER2-positive breast cancer. Sci Rep (2013) 1.14
Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer. Int J Breast Cancer (2011) 1.10
A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol Ther (2008) 1.04
Models for prevention and treatment of cancer: problems vs promises. Biochem Pharmacol (2009) 1.04
Primary trastuzumab resistance: new tricks for an old drug. Ann N Y Acad Sci (2010) 1.03
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment. Wien Med Wochenschr (2010) 1.02
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells. Cancer Immunol Immunother (2008) 0.99
A common glycan structure on immunoglobulin G for enhancement of effector functions. Proc Natl Acad Sci U S A (2015) 0.99
Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells. Oncoimmunology (2012) 0.97
Trastuzumab Sensitizes Ovarian Cancer Cells to EGFR-targeted Therapeutics. J Ovarian Res (2010) 0.93
Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer. Int J Breast Cancer (2012) 0.92
The emerging importance of α-L-fucose in human breast cancer: a review. Am J Transl Res (2011) 0.89
A FcγRIII-engaging bispecific antibody expands the range of HER2-expressing breast tumors eligible to antibody therapy. Oncotarget (2014) 0.84
Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance. Clin Breast Cancer (2013) 0.83
Small-molecule inhibitors of DNA damage-repair pathways: an approach to overcome tumor resistance to alkylating anticancer drugs. Future Med Chem (2012) 0.83
Changing strategies for target therapy in gastric cancer. World J Gastroenterol (2016) 0.81
Two novel human anti-ErbB2 immunoagents are active on trastuzumab-resistant tumours. Br J Cancer (2010) 0.81
Targeting breast cancer stem cells with HER2-specific antibodies and natural killer cells. Am J Cancer Res (2013) 0.80
Targeting HER2 Positive Breast Cancer with Chemopreventive Agents. Curr Pharmacol Rep (2015) 0.80
One target, different effects: a comparison of distinct therapeutic antibodies against the same targets. Exp Mol Med (2011) 0.79
Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy. Breast Cancer (Auckl) (2012) 0.79
Development and Characterization of a Humanized Anti-HER2 Antibody HuA21 with Potent Anti-Tumor Properties in Breast Cancer Cells. Int J Mol Sci (2016) 0.79
Long-Term Partial Remission with Capecitabine/Trastuzumab in a Patient with Metastatic Breast Cancer Following Progression on Trastuzumab Alone. Breast Care (Basel) (2012) 0.78
Current treatment of early breast cancer: adjuvant and neoadjuvant therapy. F1000Res (2014) 0.78
Inhibition of ERBB2-overexpressing Tumors by Recombinant Human Prolidase and Its Enzymatically Inactive Mutant. EBioMedicine (2015) 0.78
ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology. Cancers (Basel) (2017) 0.77
Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma. J Clin Exp Oncol (2015) 0.77
Binding of trastuzumab to ErbB2 is inhibited by a high pericellular density of hyaluronan. J Histochem Cytochem (2012) 0.77
Mild hyperthermia influence on Herceptin(®) properties. Radiol Oncol (2015) 0.77
New clinical advances in immunotherapy for the treatment of solid tumours. Immunology (2015) 0.76
Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. Mol Clin Oncol (2015) 0.76
IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM). Oncotarget (2016) 0.75
The strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicity. PLoS One (2014) 0.75
Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3). Med Chem (Los Angeles) (2013) 0.75
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 Trial. JAMA Oncol (2016) 0.75
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer. Breast Cancer Res (2017) 0.75
Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1. Oncotarget (2016) 0.75
Her2/neu Expression in Wilms' Tumor and Correlation With Histopathologic Findings. Iran J Cancer Prev (2013) 0.75
Dual inhibition of ErbB1 and ErbB2 in cancer by recombinant human prolidase mutant hPEPD-G278D. Oncotarget (2016) 0.75
Is the skin a sanctuary for breast cancer cells during treatment with anti-HER2 antibodies? Cancer Biol Ther (2015) 0.75
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol (2017) 0.75
Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model. Oncol Lett (2017) 0.75
Functionally Active Fc Mutant Antibodies Recognizing Cancer Antigens Generated Rapidly at High Yields. Front Immunol (2017) 0.75
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med (2006) 9.85
Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res (2002) 5.99
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A (2007) 5.44
Risk for distant recurrence of breast cancer detected by mammography screening or other methods. JAMA (2004) 4.01
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet (2007) 3.95
Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res (2002) 3.70
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol (2009) 3.63
ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res (2010) 3.54
KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol (2004) 2.61
Web-based virtual microscopy in teaching and standardizing Gleason grading. Hum Pathol (2005) 2.56
Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther (2004) 2.47
Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res (2005) 2.39
CGH-Plotter: MATLAB toolbox for CGH-data analysis. Bioinformatics (2003) 2.28
Autophagosomal Syntaxin17-dependent lysosomal degradation maintains neuronal function in Drosophila. J Cell Biol (2013) 2.18
Amplification of erbB2 and erbB2 expression are superior to estrogen receptor status as risk factors for distant recurrence in pT1N0M0 breast cancer: a nationwide population-based study. Clin Cancer Res (2003) 2.15
Cytogenetic alterations and cytokeratin expression patterns in breast cancer: integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest (2002) 2.06
Thioacetamide-induced hepatic fibrosis in transforming growth factor beta-1 transgenic mice. Eur J Gastroenterol Hepatol (2004) 2.06
Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancer. Genes Chromosomes Cancer (2002) 2.04
HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Lancet Oncol (2011) 2.01
Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells. Cancer Res (2005) 1.93
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res (2007) 1.91
Current perspectives on HER2 testing: a review of national testing guidelines. Mod Pathol (2003) 1.87
Frequent amplification of 8q24, 11q, 17q, and 20q-specific genes in pancreatic cancer. Genes Chromosomes Cancer (2002) 1.81
CIP2A is associated with human breast cancer aggressivity. Clin Cancer Res (2009) 1.81
The application of JPEG2000 in virtual microscopy. J Digit Imaging (2007) 1.76
Polysulfides link H2S to protein thiol oxidation. Antioxid Redox Signal (2013) 1.70
A web-based system for individualised survival estimation in breast cancer. BMJ (2003) 1.70
Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol (2009) 1.70
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol (2004) 1.70
Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. Mol Ther (2007) 1.68
Patterns of chromosomal imbalances defines subgroups of breast cancer with distinct clinical features and prognosis. A study of 305 tumors by comparative genomic hybridization. Cancer Res (2003) 1.65
Estrogen receptor beta expression is associated with tamoxifen response in ERalpha-negative breast carcinoma. Clin Cancer Res (2007) 1.54
Few FH mutations in sporadic counterparts of tumor types observed in hereditary leiomyomatosis and renal cell cancer families. Cancer Res (2002) 1.54
Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth. Mol Biol Cell (2005) 1.53
Molecular subtypes of breast cancers detected in mammography screening and outside of screening. Clin Cancer Res (2008) 1.53
HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin Cancer Res (2002) 1.53
Alterations of the SDHD gene locus in midgut carcinoids, Merkel cell carcinomas, pheochromocytomas, and abdominal paragangliomas. Genes Chromosomes Cancer (2002) 1.51
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol Cancer Res (2006) 1.51
Lipid rafts and the local density of ErbB proteins influence the biological role of homo- and heteroassociations of ErbB2. J Cell Sci (2002) 1.48
Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization. Clin Cancer Res (2004) 1.46
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med (Berl) (2006) 1.43
3-Phosphoinositide-dependent kinase 1 potentiates upstream lesions on the phosphatidylinositol 3-kinase pathway in breast carcinoma. Cancer Res (2009) 1.43
Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study. Breast Cancer Res (2011) 1.42
Effect of esomeprazole triple therapy on eradication rates of Helicobacter pylori, gastric ulcer healing and prevention of relapse in gastric ulcer patients. Eur J Gastroenterol Hepatol (2008) 1.42
Linking whole-slide microscope images with DICOM by using JPEG2000 interactive protocol. J Digit Imaging (2009) 1.39
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo. Breast Cancer Res (2011) 1.39
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod Pathol (2005) 1.38
Basoluminal carcinoma: a new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res (2006) 1.38
Association of Wwox with ErbB4 in breast cancer. Cancer Res (2007) 1.37
Biallelic inactivation of fumarate hydratase (FH) occurs in nonsyndromic uterine leiomyomas but is rare in other tumors. Am J Pathol (2004) 1.37
Cyclin-dependent kinase 5 regulates endothelial cell migration and angiogenesis. J Biol Chem (2010) 1.35
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells. Cancer Lett (2010) 1.35
High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer. Neoplasia (2004) 1.33
EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer (2008) 1.31
ImmunoMembrane: a publicly available web application for digital image analysis of HER2 immunohistochemistry. Histopathology (2012) 1.30
Haplo-insufficiency of BRCA1 in sporadic breast cancer. Cancer Res (2003) 1.27
Interaction of the HOPS complex with Syntaxin 17 mediates autophagosome clearance in Drosophila. Mol Biol Cell (2014) 1.27
IL-2 and IL-15 receptor alpha-subunits are coexpressed in a supramolecular receptor cluster in lipid rafts of T cells. Proc Natl Acad Sci U S A (2004) 1.25
Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients. Clin Cancer Res (2003) 1.23
The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Res Treat (2005) 1.21
Loss of the starvation-induced gene Rack1 leads to glycogen deficiency and impaired autophagic responses in Drosophila. Autophagy (2012) 1.21
Trastuzumab emtansine: mechanisms of action and drug resistance. Breast Cancer Res (2014) 1.21
Grading of neuroendocrine tumors with Ki-67 requires high-quality assessment practices. Am J Surg Pathol (2012) 1.20
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol (2011) 1.19
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer. Cancer Lett (2011) 1.18
Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer. Breast Cancer Res Treat (2007) 1.14
Active site of mycobacterial dUTPase: structural characteristics and a built-in sensor. Biochem Biophys Res Commun (2008) 1.14
Ski-related novel protein N (SnoN), a negative controller of transforming growth factor-beta signaling, is a prognostic marker in estrogen receptor-positive breast carcinomas. Cancer Res (2003) 1.14
Influence of obesity on lymph node recovery from rectal resection specimens. Pathol Oncol Res (2003) 1.13
Transglutaminase 2 is needed for the formation of an efficient phagocyte portal in macrophages engulfing apoptotic cells. J Immunol (2009) 1.13
Characterization of a novel breast carcinoma xenograft and cell line derived from a BRCA1 germ-line mutation carrier. Lab Invest (2003) 1.10
Copy number alterations of the polycomb gene BMI1 in gliomas. Acta Neuropathol (2008) 1.09
On the kinetics and mechanism of the reaction of cysteine and hydrogen peroxide in aqueous solution. J Pharm Sci (2006) 1.09
Web-based virtual microscopy for parasitology: a novel tool for education and quality assurance. PLoS Negl Trop Dis (2008) 1.08
Allelic length of a CA dinucleotide repeat in the egfr gene correlates with the frequency of amplifications of this sequence--first results of an inter-ethnic breast cancer study. J Pathol (2004) 1.08
Aurora-A overexpression and aneuploidy predict poor outcome in serous ovarian carcinoma. Gynecol Oncol (2011) 1.07
Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1. Immunol Lett (2005) 1.06
Die hard: are cancer stem cells the Bruce Willises of tumor biology? Cytometry A (2009) 1.06
Novel calibration method for flow cytometric fluorescence resonance energy transfer measurements between visible fluorescent proteins. Cytometry A (2005) 1.06
Aurora-A gene is frequently amplified in basal-like breast cancer. Oncol Rep (2010) 1.05
Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer (2003) 1.04
Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer. Eur J Cancer (2007) 1.04